← Leaderboards
Michael Scott Gordon
Friends Research Institute, Inc.
$19,460,241
Attributed
$32,378,188
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,378,188 · 14
By mechanism
R01$13,737,772 · 5
UG1$11,571,703 · 1
R33$1,402,656 · 1
UM1$1,393,922 · 1
UG3$1,128,686 · 1
R61$1,107,431 · 1
Top collaborators
- Thomas Blue6 shared
- Shannon Gwin Mitchell6 shared
- Josiah D Rich6 shared
- Curt G Beckwith5 shared
- Lauren Brinkley-Rubinstein5 shared
- Steven Bernard Carswell4 shared
Most similar at Friends Research Institute, Inc.
Same institution · by research overlap
- Timothy W Kinlock$10,085,018
- Thomas Blue$3,451,199
- Steven Bernard Carswell$4,215,696
Others in their field
Top investigators on “Imprisonment”
- Jeffrey H Samet · Boston University Medical Campus$82,058,793
- Linda A Teplin · Northwestern University$29,668,810
- Emily Ai-Hua Wang · Yale University$22,073,061
- Frederick Lewis Altice · Yale University$20,463,555
- Brian Richard Smith · Yale University$19,789,874
- John H Krystal · Yale University$19,789,874
Research focus
ImprisonmentCommunitiesInnovationRisk BehaviorsRandomizedPharmaceutical PreparationsSiteUrineDrug UsageHiv RiskDesignCriminal JusticePublic HealthWomanSafetyProgramsMental HealthPrisonsFundingParticipantMarylandSupervisionEffectivenessOpioid
Grant awards (42)
NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings$1,402,656
R33 · FY2025 · DA
A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail$1,393,922
UM1 · FY2025 · DA
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$1,129,361
R01 · FY2025 · DA · contact PI
NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings$1,107,431
R61 · FY2024 · DA
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$1,086,043
R01 · FY2024 · DA · contact PI
Continuing Care App for Justice-Involved Individuals with Substance Use Disorders$555,180
UG3 · FY2024 · DA · contact PI
Long-acting injectable antiretroviral treatment to improve HIV treatment among justice-involved persons being released to the community$231,115
R34 · FY2024 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$1,967,149
UG1 · FY2023 · DA · contact PI
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$881,830
R01 · FY2023 · DA · contact PI
Continuing Care App for Justice-Involved Individuals with Substance Use Disorders$573,506
UG3 · FY2023 · DA · contact PI
Buprenorphine for probationers and parolees: Bridging the gap into treatment$562,665
R01 · FY2023 · DA · contact PI
Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment$444,092
UG1 · FY2023 · DA · contact PI
Long-acting injectable antiretroviral treatment to improve HIV treatment among justice-involved persons being released to the community$273,844
R34 · FY2023 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,169,367
UG1 · FY2022 · DA · contact PI
A comparison of Sublingual and Extended-Release Buprenorphine for Individuals Leaving Jail$678,563
UG1 · FY2022 · DA · contact PI
Buprenorphine for probationers and parolees: Bridging the gap into treatment$627,397
R01 · FY2022 · DA · contact PI
Long-acting injectable antiretroviral treatment to improve HIV treatment among justice-involved persons being released to the community$212,352
R34 · FY2022 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,216,013
UG1 · FY2021 · DA · contact PI
Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment$519,501
R01 · FY2021 · DA · contact PI
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$165,428
UG1 · FY2021 · DA · contact PI
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,231,473
UG1 · FY2020 · DA · contact PI
Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment$637,817
R01 · FY2020 · DA · contact PI
Buprenorphine for probationers and parolees: Bridging the gap into treatment$628,448
R01 · FY2020 · DA · contact PI
Continuing Care App for Probationers and Parolees with Substance Use Disorders$452,547
R44 · FY2020 · MD
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$1,699,618
UG1 · FY2019 · DA · contact PI
Buprenorphine for probationers and parolees: Bridging the gap into treatment$628,448
R01 · FY2019 · DA · contact PI
Buprenorphine for probationers and parolees: Bridging the gap into treatment$599,398
R01 · FY2019 · DA · contact PI
Continuing Care App for Probationers and Parolees with Substance Use Disorders$546,245
R44 · FY2019 · MD
Buprenorphine for probationers and parolees: Bridging the gap into treatment$639,465
R01 · FY2018 · DA · contact PI
Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment$631,303
R01 · FY2018 · DA · contact PI
Buprenorphine for probationers and parolees: Bridging the gap into treatment$346,933
R01 · FY2018 · DA · contact PI
Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment$631,303
R01 · FY2017 · DA · contact PI
Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment$644,996
R01 · FY2016 · DA · contact PI
Continuing Care App for Probationers and Parolees with Substance Use Disorders$169,928
R41 · FY2015 · MD · contact PI
Avatar Assisted Therapy for Probationers and Parolees with Substance Use Disorders$149,987
R41 · FY2015 · MD · contact PI
A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care$131,653
R01 · FY2015 · DA · contact PI
A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care$400,607
R01 · FY2014 · DA · contact PI
A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care$654,674
R01 · FY2013 · DA · contact PI
A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care$685,112
R01 · FY2012 · DA · contact PI
Treatment Study Using Depot Naltrexone(5/6)Baltimore Protocol Treatment Site$200,505
R01 · FY2012 · DA · contact PI
A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care$731,641
R01 · FY2011 · DA · contact PI
A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care$738,672
R01 · FY2010 · DA · contact PI